HC@AIxIA: AI&Health Seminar Series (2024) - JULY 11

[*apologize for multiple postings*]

Dear Madam/Sir,

This is to officially announce the SEVENTH seminar of the "AI & Health"
series as hosted by HC@AIxIA, i.e., the "Artificial Intelligence for
Healthcare" working group of the Italian Association for Artificial
Intelligence. *Save the date: 11 JULY 2024.*

We hope you will attend and participate in the discussion on the relevant
topics that will be presented and by our speakers.

*Feel free to share this with those potentially interested.*
Please find some details below, and a poster attached. All directions for
participating are available at https://aixia.it/en/gruppi/hc/.

*== Are you interested in Joining the group? ==*
Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not
hesitate to contact us at hc-aixia@googlegroups.com for any information or
clarification.


Thank you for your interest in the AI & Health seminar series and
the HC@AIxIA working group, and see you soon!

Sincerely,
Francesco Calimeri, Mauro Dragoni, Fabio Stella
(coordinators of the HC@AIxIA working group)



*== July 2024 seminar ==*
*Link to participate: *
https://unimib.webex.com/unimib/j.php?MTID=m823bedbf7311facb23486a3a1ac27e76

*2024 June 17 - 4:30PM CET*
*Alberto Mussetti, *Hematology Department, Institut Català d'Oncologia
(Barcelona, Spain)

*Title*: The Quantum Leap: AI and Telemedicine Unveiling the Next Frontier
in Allogeneic Hematopoietic Stem Cell Transplantation

*Abstract*: This conference explores the transformative intersection of
Artificial Intelligence (AI) and Telemedicine in the realm of Allogeneic
Hematopoietic Cell Transplantation (allo-HCT), heralding a new era in
healthcare. The discussion delves into the potential of these advanced
technologies to reshape the landscape of allo-HCT, promising enhanced
accessibility, efficiency, and patient outcomes. The conference begins by
examining how AI algorithms are revolutionizing donor matching processes
and patient assessments, refining the selection of recipients and
minimizing complications. Furthermore, the integration of telemedicine
platforms facilitates remote patient monitoring, enabling real-time
tracking of vital health indicators and facilitating timely interventions.
As AI and telemedicine converge to reshape the landscape of allo-HSCT, this
discussion serves as a pivotal exploration into the advantages and limits
of this transformative journey.

*Short Bio*: Alberto Mussetti MD, works at the Hematology Department at
Institut Català d'Oncologia (Barcelona, Spain) as Director of the
Hematopoietic Cell Transplantation and Cell Therapy Unit. During the last
years his research has been focused on lymphoid malignancies, allogeneic
hematopoietic cell transplant and digital medicine. He previously worked at
Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)and Memorial
Sloan Kettering Cancer Center of New York. He is an active participant and
principal investigator of the Lymphoma Working party of the European Bone
Marrow Transplantation Society (EBMT) and the Center for International Bone
Marrow Transplant Research (CIBMTR).


[image: HC@AIxIA - Seminars AI & Health 2024 - Locandina 07.png]